QTOF Technology for Targeted and Unknown Forensic Drugs Screening Workflows

Feb 22, 2016 | Blogs, Forensic | 0 comments

In this study, the Wisconsin State Laboratory of Hygiene (WSLH) outlines the comparison of their existing technology and how SCIEX LC-MS/MS systems can assist them in their forensic research. The WSLH routinely analyze for 300 forensic drug compounds in over 18,000 samples per year.

The highly laborious workflows they used to perform this routine analysis relied upon EMIT, HPLC (with wavelength detection) GC/NPD and GC-MS. The nature of the ever-changing forensic drug testing environment means that it is difficult to identify the widely varying synthetic cannabinoids and novel psychoactive substances. 

The purpose of this study was to investigate whether the adoption of QTOF technology for targeted and unknown forensic drugs screening workflows are sensitive and reliable to achieve these goals. The instrument of choice for this study was the TripleTOF® 5600+ system.

In the video below Adrian Taylor, Forensics Application Manager at SCIEX delivers an overview of the poster presentation for this study which was displayed at the annual TiAFT conference in Firenze, Italy. Download Poster >

Routine forensic drug testing has recently been given a boost with the launch of the X500R QTOF system, this system is designed specifically for routine forensic toxicology analysis. The X500R coupled with the brand new software application, SCIEX OS, delivers an all-encompassing solution for forensic drug screening. The intuitive workflows are ideally suited for the analysis of Synthetic Cannabinoids, Novel Psychoactive Substance. We have also produced a comprehensive library of compounds to assist with your analysis, this library contains over 1700 compounds with full acquired spectral data.

If your lab is using old technology, we want to hear from you. Tell us what kind of experiments you are running and what are the setbacks you have encountered?

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

0 Comments

Submit a Comment

Pin It on Pinterest

Share This

Share this post with your network